# 2026-03713: FDA's New Playbook for Custom Gene Fixes Gets Public Input

2026-03713, Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-02-25, effective Submit either electronic or written comments on the draft guidance by April 27, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-03713
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-03713
- Title: Considerations for the Use of the Plausible Mechanism Framework To Develop Individualized Therapies That Target Specific Genetic Conditions With Known Biological Cause; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 9283
- Published: 2026-02-25
- Effective: Submit either electronic or written comments on the draft guidance by April 27, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.
- Comments close: 2026-04-27
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA's New Playbook for Custom Gene Fixes Gets Public Input

## Summary

The FDA just dropped a draft guide to help drug makers create personalized treatments for genetic conditions with known causes. This new approach focuses on proving these therapies work and are safe using a smart, science-based method. Companies and patients can weigh in by April 27, 2026, shaping how these life-changing treatments get developed and approved faster.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft document entitled "Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause." The draft guidance document describes considerations for generating substantial evidence of effectiveness and evidence of safety of individualized therapies based on a plausible mechanism framework.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-03713 on federalregister.gov](https://www.federalregister.gov/documents/2026/02/25/2026-03713/considerations-for-the-use-of-the-plausible-mechanism-framework-to-develop-individualized-therapies)
- [2026-03713 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-02-25/pdf/2026-03713.pdf)

## Related
- [Previous: 2026-03712, Proposed Information Collection Activity; Tribal Maternal, Infant, and Early Ch…](https://policyrisk.com/federal-register/2026-03712)
- [Next: 2026-03714, Duke Energy Carolinas, LLC; Belews Creek; Early Site Permit Application](https://policyrisk.com/federal-register/2026-03714)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-03713 (as of 2026-06-08).
